With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
June 8, 2017. Prostate-specific antigen (PSA) doubling time, time to PSA failure, PSA nadir. We've heard them all, but how do you make sense of them? Especially when counselling anxious men whose post-radiation PSA changes like ocean sea levels (looking at you, Al Gore). In a secondary analysis of the D'Amico trial of radiation +/- 6 months androgen deprivation therapy for intermediate risk prostate cancer, PSA failure was useless for predicting death. However, failure within 30 months, PSA doubling time < 9 months, and especially nadir > 0.5 did predict death. If you see these, get serious. Oh yeah, and melting permafrost is threatening the world seed bank (that's for you, Al).